Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
6 hedge funds and large institutions have $395K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
98% more capital invested
Capital invested by funds: $200K → $395K (+$195K)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
+$5.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$27K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $159K | – | – | – |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $150K | – | – | – |
|
|
MWNA
3
Marshall Wace North America
New York
| $45K | – | – | – |
|
|
PC
4
PointState Capital
New York
| $35K | – | – | – |
|
|
ICM
5
Ionic Capital Management
New York
| $6K | +$5.72K | +17,826 | New |
|
|
SM
6
Sabby Management
Miami Beach,
Florida
| – | -$27K | -177,439 | Closed |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$4K | -24,311 | Closed |
|
|
RIA
8
Realta Investment Advisors
Wilmington,
Delaware
| – | +$160 | +500 | New |
|
OTLKW Hedge Fund Activity: Q1 2019 in Review
6 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q1 2019, worth a combined $395K — up 98% from $200K a quarter earlier.
Fund positioning in OTLKW was balanced in Q1 2019: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Ionic Capital Management, opening a new position worth an estimated $5.72K. The largest seller was Sabby Management, exiting entirely with an estimated $27K sold.
- 6 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $395K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q1 2019, up 98% quarter-over-quarter.
- 2 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q1 2019 and 2 closed out, a net change of 0 holders.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q1 2019 was Ionic Capital Management, an estimated $5.72K added.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q1 2019 was Sabby Management, an estimated $27K sold.
Based on aggregated 13F filings for Q1 2019.